Sirolimus

CAS 53123-88-9 16 current records 4 historicalSmall Molecule

Who holds supplier records for Sirolimus? 16 organisations hold a current record for Sirolimus: an active US FDA Type II Drug Master File. A further 4 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: China (4), India (2), United States (1), Canada (1) and 1 other country (1); not recorded for 7.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Sirolimus: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/sirolimus

Reading the evidence

  • 16 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 5 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Sirolimus expires 11 Apr 2045. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (16)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Sirolimus. Country is the organisation's recorded country, not necessarily the manufacturing site.

China4India2United States1Canada1Italy1Country not recorded for 7
  • CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD
    Active DMF 17399, 31189 · latest filing Dec 2016
    Company GMP cert on record
  • LUNAN NEW TIME BIO-TECH CO LTD
    Active DMF 29440, 36858 · latest filing Jan 2024
  • NOVARTIS PHARMACEUTICALS CORP
    Active DMF 15720, 28023 · latest filing Mar 2014
    United States Company GMP cert on record
  • Apotex Inc.
    Active DMF 26904 · latest filing Feb 2013
    Canada
  • Biocon Limited
    Active DMF 21571 · latest filing Apr 2008
    India
  • BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD
    Active DMF 35527 · latest filing Apr 2021
    China
  • Chongqing Daxin Pharmaceutical Co., Ltd.
    Active DMF 31052 · latest filing Oct 2016
    China
  • CONCORD BIOTECH LTD
    Active DMF 24468 · latest filing Feb 2011
    India Company GMP cert on record
  • CURIA ITALY SRL
    Active DMF 21037 · latest filing Nov 2007
    Italy Company GMP cert on record
  • FUJIAN KERUI PHARMACEUTICAL CO LTD
    Active DMF 16890 · latest filing Oct 2003
    China
  • HANGZHOU HUADONG MEDICINE GROUP KANGRUN PHARMACEUTICAL CO LTD
    Active DMF 26983 · latest filing Mar 2013
    China
  • HEILONGJIANG WEIKAIER BIOTECHNOLOGY CO LTD
    Active DMF 31527 · latest filing Dec 2017
  • HISUN PHARMACEUTICAL HANGZHOU CO LTD
    Active DMF 27725 · latest filing Dec 2013
  • LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTD
    Active DMF 35478, 35043 · latest filing Dec 2020
    Company GMP cert on record
  • PARTNERS PHARMACEUTICALS INC
    Active DMF 32414, 35023 · latest filing Jul 2020
  • YANGZHOU LIANAO BIOPHARMACEUTICAL CO LTD
    Active DMF 37091, 33075 · latest filing Apr 2022
Need Sirolimus sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (4)

Organisations whose Type II DMFs for Sirolimus are no longer active. These show a past filing, not current supply.

Show all 4 historical records

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (23 listed products contain Sirolimus). The latest listed patent expires 11 Apr 2045. The latest listed exclusivity runs to 22 Mar 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Sirolimus, also known as rapamycin, is an immunosuppressive drug commonly used to prevent organ transplant rejection. It works by inhibiting the mammalian target of rapamycin (mTOR), which plays a crucial role in cell growth and proliferation.

Chemical identity

IUPAC name
1,18-dihydroxy-12-[1-(4-hydroxy-3-methoxycyclohexyl)propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Canonical SMILES
CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC
InChIKey
QFJCIRLUMZQUOT-UHFFFAOYSA-N
Synonyms
Rapamune API, Rapamycin-d3, 28-Epirapamycin, SiroliMus-D3/RapaMycin-D3, (RS)-rapamycin, SpecPlus_000840, DivK1c_006936, KBio1_001880, DKA43135, SQA71119, Rapamycin; Everolimus EP Impurity A, Q27163227

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Kinase Inhibitor; mTOR Inhibitor Immunosuppressant
Mechanism of action
mTOR Inhibitors; Protein Kinase Inhibitors
Physiologic effect
Decreased Immunologic Activity

Therapeutic areas

Immunosuppressive AgentsOrgan TransplantationAntineoplastic Agents

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Sirolimus?

16 organisations hold an active US FDA Type II Drug Master File or a CEP for Sirolimus: CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD, LUNAN NEW TIME BIO-TECH CO LTD, NOVARTIS PHARMACEUTICALS CORP (United States), Apotex Inc. (Canada), Biocon Limited (India), BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD (China), Chongqing Daxin Pharmaceutical Co., Ltd. (China) and CONCORD BIOTECH LTD (India), and 8 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Sirolimus Drug Master Files are active?

CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD (DMF 17399, 31189), LUNAN NEW TIME BIO-TECH CO LTD (DMF 29440, 36858), NOVARTIS PHARMACEUTICALS CORP (DMF 15720, 28023), Apotex Inc. (DMF 26904), Biocon Limited (DMF 21571), BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD (DMF 35527), Chongqing Daxin Pharmaceutical Co., Ltd. (DMF 31052) and CONCORD BIOTECH LTD (DMF 24468) and 8 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Sirolimus records mean?

4 organisations have only inactive Type II DMFs for Sirolimus. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does the FDA Orange Book list patents for products containing Sirolimus?

Yes. The latest patent listed for an approved US product containing Sirolimus expires 11 Apr 2045, across 23 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Sirolimus supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Sirolimus?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.